Table 4.
Data on the prevalence of hypermetabolic lymph nodes at 2-[18F]FDG PET/CT after injection of other vaccines beyond COVID-19.
| Authors and Year | Target of Vaccination | Time Interval from Vaccine Injection to 2-[18F]FDG PET/CT Scan (Days) | Cases Evaluated with 2-[18F]FDG PET/CT after Vaccination | ||
|---|---|---|---|---|---|
| HyperMetabolic LN Present | HyperMetabolic LN Present | Uptake at Injection Site of Vaccine | |||
| Burger et al. 2011 [22] | Influenza | 1–30 | 17/58 (29%) |
41/58 (71%) |
17/58 (29%) |
| Coates et al. 2017 [23] | Papillomavirus | 8–37 | 15/15 (100%) |
0/15 (0%) |
NA |
| Iyenga et al. 2003 [24] | Influenza | 3–5 | 7/8 (87%) |
1/8 (13%) |
NA |
| Nakata et al. 2021 [25] | Anti-cancer | 1–1159 | NA | NA | 33/37 (89%) |
| Panagiotidis et al. 2010 [26] | Influenza | 2–18 | 10/10 (100%) |
0/10 (0%) |
NA |
| Shirone et al. 2012 [27] | Influenza | <7 or ≥7 | 4/83 (5%) |
79/83 (95%) |
NA |
| Thomassen et al. 2011 [28] | Influenza | 1–330 | NA | NA | NA |
| Win et al. 2021 [29] | Several types of viruses | 1–10 | 38/53 (72%) |
15/53 (28%) |
NA |
Legend: 2-[18F]FDG = fluorine-18 fluorodeoxyglucose; 95%CI = 95% confidence interval; LN = lymph nodes; NA = not available or calculable; PET/CT = positron emission tomography/computed tomography.